학술논문
Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review.
Document Type
Academic Journal
Author
Hirose T; Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.; Chen CC; Division of Endocrinology and Metabolism, Department of Medicine, China Medical University Hospital, Taichung, Taiwan.; China Medical University School of Chinese Medicine, Taichung, Taiwan.; Ahn KJ; Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.; Kiljański J; Eli Lilly Polska, Warsaw, Poland. kiljanski_jacek@lilly.com.
Source
Publisher: Springer Healthcare Country of Publication: United States NLM ID: 101539025 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1869-6953 (Print) Linking ISSN: 18696961 NLM ISO Abbreviation: Diabetes Ther Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
1869-6953
Abstract
Insulin glargine (IGlar) 100 U/mL (IGlar-100) is widely used in East Asian countries for the treatment of type 2 diabetes mellitus (T2DM) and is the gold standard of basal insulin treatment. In this review we summarize key information about clinical experience with IGlar-100 in East Asian patients with T2DM, including findings from clinical trials and postmarketing studies. We also provide recommendations and opinions on the optimal use of IGlar-100 in this population. The findings from the studies highlighted in our review indicate that IGlar-100 can be a suitable treatment option for East Asians with T2DM, from initial therapy in combination with oral antihyperglycemic medications through to different combinations and intensification models. FUNDING: Eli Lilly and Company.